OPK
OPKO Health, Inc.
OPK has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over OPK overall, supported by stronger fundamentals and stronger modeled upside.
OPK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OPK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OPK PE Valuation
OPK has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OPK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect OPK's revenue and profitability to decline, with its earnings holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over OPK on the outlook, with more favorable earnings and revenue expectations.
OPK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.06 |
| Q2 2026 | -$0.09 | +$0.16 |
| Q1 2026 | -$0.27 | -$0.20 |
| Q4 2025 | -$0.30 | -$0.21 |
| Q3 2025 | -$0.25 | -$0.06 |
| Q2 2025 | -$0.25 | +$0.08 |
| Q1 2025 | -$0.07 | +$0.28 |
| Q4 2024 | -$0.09 | +$0.16 |
OPK is still losing money, but far less than before: $0.19 per share over the past year, against $0.53 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over OPK on earnings quality, reporting a profit while its opponent remains loss making.
OPK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $65.4M | -57% |
| Q2 2026 | $163.6M | +4.3% |
| Q1 2026 | $124.2M | -17% |
| Q4 2025 | $148.5M | -19% |
| Q3 2025 | $151.7M | -13% |
| Q2 2025 | $156.8M | -14% |
| Q1 2025 | $150M | -14% |
| Q4 2024 | $183.6M | +1% |
OPK's revenue has slid since its 2021 peak: $65M last quarter, down 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -48% | -80 points |
| Q2 2026 | -4.3% | +34 points |
| Q1 2026 | -41% | +3.7 points |
| Q4 2025 | -26% | -7.8 points |
| Q3 2025 | 32% | +24 points |
| Q2 2025 | -38% | -4.4 points |
| Q1 2025 | -45% | -3.6 points |
| Q4 2024 | -18% | +20 points |
OPK's operating margin was −48% last quarter, down 80 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OPK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over OPK on profitability, with a higher operating margin.
OPK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.1M | -$1.3M |
| Q2 2026 | -$46.5M | +$40.2M |
| Q1 2026 | -$21.1M | +$16.6M |
| Q2 2025 | -$86.7M | -$53.1M |
| Q1 2025 | -$37.7M | +$2.3M |
| Q2 2024 | -$33.7M | -$27.3M |
| Q1 2024 | -$40M | -$14.3M |
| Q4 2023 | -$41.3M | -$3.4M |
OPK has burned cash in most quarters: −$135M over the past year, against −$196M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OPK on cash generation, producing positive trailing cash flow while its opponent burns cash.
OPK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -8.8M shares |
| 1 year | -4.3% | -33.4M shares |
| 3 years | -0.7% | -5M shares |
| 5 years | +15% | +94.6M shares |
| Available history | +25% | +151M shares |
OPK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10.6M |
| Q2 2026 | $13M |
| Q1 2026 | $4.8M |
| Q4 2025 | $13.5M |
| Q3 2025 | $15.3M |
| Q2 2025 | $18.3M |
| Q1 2025 | — |
| Q4 2024 | $16.5M |
OPK spent $42M buying back its own shares over the past year, down 16% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OPK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -7.2x | Net Cash |
| Q4 2021 | 0.7x | Very low |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.3x | Net Cash |
| Q1 2021 | -0.4x | Net Cash |
| Q4 2020 | 1.3x | Healthy |
OPK has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
OPK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.9 | Neutral |
| Stochastic | 74.7 | Neutral |
OPK's weekly RSI is 59 (neutral) and its Stochastic is 75 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OPK PE vs Healthcare Sector
| Metric | OPK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
OPK has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OPK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.60 | 4.4% above |
| 20 week MA | $1.50 | 11% above |
| 50 week MA | $1.36 | 23% above |
| 100 week MA | $1.40 | 19% above |
| 200 week MA | $1.42 | 18% above |
OPK has climbed back above all five of its weekly moving averages, and it's now 18% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
OPK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.50 | $4.23 | +182% |
| 2021 | $4.23 | $4.77 | +13% |
| 2022 | $4.77 | $1.14 | -76% |
| 2023 | $1.14 | $1.51 | +32% |
| 2024 | $1.51 | $1.48 | -2% |
| 2025 | $1.48 | $1.29 | -13% |
| 2026 YTD | $1.29 | $1.67 | +29% |
OPK's yearly returns have swung widely, from +182% in 2020 to −76% in 2022. It's up 29% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OPK on returns for 2026, with the stronger performance.